Nonpeptidic urotensin-II receptor antagonists I: In vitro pharmacological characterization of SB-706375

British Journal of Pharmacology

Volumn 145, Issue 5, 2005, Pages 620-635

  Douglas, Stephen A ^a   Behm, David J ^a   Aiyar, Nahim V ^a   Naselsky, Diane ^a   Disa, Jyoti ^a   Brooks, David P ^a   Ohlstein, Eliot H ^a   Gleason, John G ^a   Sarau, Henry M ^a   Foley, James J ^a   Buckley, Peter T ^a   Schmidt, Dulcie B ^a   Wixted, William E ^a   Widdowson, Katherine ^a   Riley, Graham ^b   Jin, Jian ^a   Gallagher, Timothy F ^a   Schmidt, Stanley J ^a   Ridgers, Lance ^a   Christmann, Lisa T ^a   Keenan, Richard M ^a   Knight, Steven D ^a   Dhanak, Dashyant ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

G protein coupled receptor; GPR 14; Heart failure; Hypertension; Radioligand binding; SB 657510; SB 706375; Urotensin; UT receptor; Vasoconstriction

Indexed keywords

2 BROMO 4,5 DIMETHOXY N [3 (1 METHYLPYRROLIDIN 3 YLOXY) 4 TRIFLUOROMETHYLPHENYL]BENZENESULFONAMIDE; 2 BROMO N [3 (4 CHLORO 1 METHYLPYRROLIDIN 3 YLOXY)PHENYL] 4,5 DIMETHOXYBENZENESULFONAMIDE; ANGIOTENSIN; CALCIUM; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; ENDOTHELIN 1; ENZYME; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR; ION CHANNEL; ISOPROTEIN; LIGAND; NONPEPTIDIC UROTENSIN II RECEPTOR BLOCKING AGENT; PHENYLEPHRINE; POTASSIUM CHLORIDE; RADIOLIGAND; RECEPTOR BLOCKING AGENT; RECOMBINANT RECEPTOR; RECOMBINANT UROTENSIN II RECEPTOR; SB 657510; SB 706375; SULFONAMIDE; UNCLASSIFIED DRUG; UROTENSIN II;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING KINETICS; CALCIUM MOBILIZATION; CAT; CELL STRAIN; CELL STRAIN HEK293; CELL STRAIN SJRH30; CROSS SPECIES ACTIVITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SELECTIVITY; HEART FAILURE; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; LIGAND BINDING; MAMMAL; MONKEY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIMATE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR DENSITY; RODENT; VASOCONSTRICTION;

ALGORITHMS; ANIMALS; AORTA, THORACIC; BINDING, COMPETITIVE; CATS; CELL LINE, TUMOR; CELL MEMBRANE; HAPLORHINI; HUMANS; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PYRROLIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; RHABDOMYOSARCOMA; SPECIES SPECIFICITY; SULFONAMIDES;

EID: 22744447609     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706229     Document Type: Article

References (65)

1. ABOUD, R., SHAFII, M. & DOCHERTY, J.R. (1993). Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br. J. Pharmacol., 109, 80-87.
2. AFFOLTER, J.T., NEWBY, D.E., WILKINSON, I.B., WINTER, M.J., BALMENT, R.J. & WEBB, D.J. (2002). No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br. J. Clin. Pharmacol., 54, 617-621.
3. AIYAR, N.V., JOHNS, D.G., AO, Z., DISA, J., BEHM, D.J., FOLEY, J.J., BUCKLEY, P.T., SARAU, H.M., VAN DER KEYL, H.K., ELSHOURBAGY, N.A. & DOUGLAS, S.A. (2005). Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). Biochem. Pharmacol., 69, 1069-1079.
4. AMES, R.S., SARAU, H.M., CHAMBERS, J.K., WILLETTE, R.N., AIYAR, N.V., ROMANIC, A.M., LOUDEN, C.S., FOLEY, J.J., SAUERMELCH, C.F., COATNEY, R.W., AO, Z., DISA, J., HOLMES, S.D., STADEL, J.M., MARTIN, J.D., LIU, W.S., GLOVER, G.I., WILSON, S., MCNULTY, D.E., ELLIS, C.E., ELSHOURBAGY, N.A., SHABON, U., TRILL, J.J., HAY, D.W., OHLSTEIN, E.H., BERGSMA, D.J. & DOUGLAS, S.A. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, 282-286.
5. BEHM, D.G., HEROLD, C.L., OHLSTEIN, E.H., KNIGHT, S.D., DHANAK, D. & DOUGLAS, S.A. (2002). Pharmacological characterization of SB-710411 (Cap-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br. J. Pharmacol., 137, 449-458.
6. BEHM, D.J., DOE, C.P., JOHNS, D.G., MANISCALCO, K., STANKUS, G.P., WIBBERLEY, A., WILLETTE, R.N. & DOUGLAS, S.A. (2004a). Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedeberg's Arch. Pharmacol., 369, 274-280.
7. BEHM, D.J., HEROLD, C.L., CAMARDA, V., AIYAR, N.V. & DOUGLAS, S.A. (2004b). Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Eur. J. Pharmacol., 25, 113-116.
8. BOHM, F. & PERNOW, J. (2002). Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol., 135, 25-27.
9. BOUSETTE, N., PATEL, L., DOUGLAS, S.A., OHLSTEIN, E.H. & GIAID, A. (2004). Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis, 176, 117-123.
10. CAMARDA, V., GUERRINI, R., KOSTENIS, E., RIZZI, A., CALO', G., HATTENBURGER, A., ZUCCHINI, M., SALVADORI, S. & REGOLI, D. (2002a). A new ligand for the urotensin II receptor. Br. J. Pharmacol., 137, 311-314.
11. CAMARDA, V., RIZZI, A., CALO', G., GENDRON, G., PERRON, S.I., KOSTENIS, E., ZAMBONI, P., MASCOLI, F. & REGOLI, D. (2002b). Effects of human urotensin II in isolated vessels of various species: comparison with other vasoactive agents. Naunyn Schmiedeberg's Arch. Pharmacol., 365, 141-149.
12. CAMARDA, V., SONG, W., MARZOLA, E., SPAGNOL, M., GUERRINI, R., SALVADORI, S., REGOLI, D., THOMPSON, J.P., ROWBOTHAM, D.J., BEHM, D.J., DOUGLAS, S., CALO', G. & LAMBERT, D.G. (2004). Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur. J. Pharmacol., 498, 83-86.
13. CHEUNG, B.M., LEUNG, R., MAN, Y.B. & WONG, L.Y. (2004). Plasma concentration of urotensin II is raised in hypertension. J. Hypertens., 22, 1341-1344.
14. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 357-366.
15. CLOZEL, M., BINKERT, C., BIRKER-ROBACZEWSKA, M., BOUKHADRA, C., DING, S.S., FISCHLI, W., HESS, P., MATHYS, B., MORRISON, K., MULLER, C., MULLER, C., NAYLER, O., QIU, C., REY, M., SCHERZ, M.W., VELKER, J., WELLER, T., XI, J.F. & ZILTENER, P. (2004). Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362: 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2- methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J. Pharmacol. Exp. Ther., 311, 204-212.
16. DHANAK, D., GALLAGHER, T.F. & KNIGHT, S.D. (2002). Preparation of sulfonamides as antagonists of urotensin II. PCT Int. Appl., WO 2002089792.
17. DHANAK, D., NEEB, M.J. & DOUGLAS, S.A. (2003). Urotensin-II receptor modulators. Ann. Rep. Med. Chem., 38, 99-110.
18. DOUGLAS, S.A. (2003). Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr. Opin. Pharmacol., 3, 159-167.
19. DOUGLAS, S.A., BECK, G.R., ELLIOTT, J.D. & OHLSTEIN, E.H. (1995). Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br. J. Pharmacol., 114, 1529-1540.
20. DOUGLAS, S.A., DHANAK, D. & JOHNS, D.G. (2004a). From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol. Sci., 25, 76-85.
21. DOUGLAS, S.A., NASELSKY, D., AO, Z., DISA, J., HEROLD, C.L., LYNCH, F. & AIYAR, N.V. (2004b). Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. Br. J. Pharmacol., 142, 921-932.
22. DOUGLAS, S.A. & OHLSTEIN, E.H. (2000). Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med., 10, 229-237.
23. DOUGLAS, S.A., SULPIZIO, A.C., PIERCY, V., SARAU, H.M., AMES, R.S., AIYAR, N.V., OHLSTEIN, E.H. & WILLETTE, R.N. (2000). Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol., 131, 1262-1274.
24. DOUGLAS, S.A., TAYARA, L., OHLSTEIN, E.H., HALAWA, N. & GIAID, A. (2002). Congestive heart failure and expression of myocardial urotensin II. Lancet, 359, 1990-1997.
25. ELSHOURBAGY, N.A., DOUGLAS, S.A., SHABON, U., HARRISON, S., DUDDY, G., SECHLER, J.L., AO, Z., MALEEFF, B.E., NASELSKY, D., DISA, J. & AIYAR, N.V. (2002). Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol., 136, 9-22.
26. GARDINER, S.M., MARCH, J.E., KEMP, P.A. & BENNETT, T. (2004). Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br. J. Pharmacol., 143, 422-430.
27. GILBERT, R.E., DOUGLAS, S.A. & KRUM, H. (2004). Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. Curr. Opin. Invest. Drugs, 5, 276-282.
28. HASEGAWA, K., KOBAYASHI, Y. & KOBAYASHI, H. (1992). Vasodepressor effects of urotensin II in rats. Neuroendocrinol. Lett., 14, 357-363.
29. HEROLD, C.L., BEHM, D.J., BUCKLEY, P.T., FOLEY, J.J. & DOUGLAS, S.A. (2002). The peptidic somatostatin analogs lanreotide, BIM-23127 and BIM-23042 are urotensin-II receptor ligands. Pharmacologist, 44, 170-171.
30. HEROLD, C.L., BEHM, D.J., BUCKLEY, P.T., FOLEY, J.J., WIXTED, W.E., SARAU, H.M. & DOUGLAS, S.A. (2003). The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br. J. Pharmacol., 139, 203-207.
31. HILLIER, C., BERRY, C., PETRIE, M.C., O'DWYER, PJ., HAMILTON, C., BROWN, A. & MCMURRAY, J. (2001). Effects of urotensin II in human arteries and veins of varying caliber. Circulation, 103, 1378-1381.
32. JOHNS, D.O., AO, Z., NASELSKY, D., HEROLD, C.L., MANISCALCO, K., SAROV-BLAT, L., STEPLEWSKI, K., AIYAR, N. & DOUGLAS, S.A. (2004). Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedeberg's Arch. Pharmacol., 370, 238-250.
33. KOMPA, A.R., THOMAS, W.G., SEE, F., TZANIDIS, A., HANNAN, R.D. & KRUM, H. (2004). Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides, 25, 1783-1788.
34. LANGHAM, R.G., KELLY, D.J., GOW, R.M., ZHANG, Y., DOWLING, J.K., THOMSON, N.M. & GILBERT, R.E. (2004). Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am. J. Kidney Dis., 44, 826-831.
35. LAPP, H., BOERRIGTER, G., COSTELLO-BOERRIGTER, L.C., JAEKEL, K., SCHEFFOLD, T., KRAKAU, I., SCHRAMM, M., GUELKER, H. & STASCH, J.P. (2004). Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int. J. Cardiol., 94, 93-97.
36. LESLIE, S.J., DENVIR, M. & WEBB, D.J. (2000). Human urotensin II causes vasoconstriction in the human skin microcirculation. Circulation, 102, 11-113.
37. LEW, M.J. & ANGUS, J.A. (1997). An improved method for analysis of competitive agonist/antagonist interactions by non-linear regression. Ann. N. Y. Acad. Sci., 812, 179-181.
38. LIM, M., HONISETT, S., SPARKES, C.D., KOMESAROFF, P., KOMPA, A. & KRUM, H. (2004). Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation, 109, 1212-1214.
39. MACLEAN, M.R., ALEXANDER, D., STIRRAT, A., GALLAGHER, M., DOUGLAS, S.A., OHLSTEIN, E.H., MORECROFT, I. & POLLAND, K. (2000). Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol., 130, 201-204.
40. MAGUIRE, J.J. & DAVENPORT, A.P. (2002). Is urotensin-II the new endothelin? Br. J. Pharmacol., 137, 579-588.
41. MAGUIRE, J.J., KUC, R.E. & DAVENPORT, A.P. (2000). Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol., 131, 441-446.
42. MAGUIRE, J.J., KUC, R.E., WILEY, K.E., KLEINZ, M.J. & DAVENPORT, A.P. (2004). Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and greater constrictor response of small compared to large coronary arteries. Peptides, 25, 1767-1774.
43. MATSUSHITA, M., SHICHIRI, M., IMAI, T., IWASHINA, M., TANAKA, H., TAKASU, N. & HIRATA, Y. (2001). Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hyper tens., 19, 2185-2190.
44. NG, L.L., LOKE, I., O'BRIEN, R.J., SQUIRE, I.B. & DAVIES, J.E. (2002). Plasma urotensin in human systolic heart failure. Circulation, 106, 2877-2880.
45. ONAN, D. (2004). Cardiovascular and regulatory aspects of the urotensin-II receptor. PhD Thesis, Monash University, Melbourne, Australia.
46. ONAN, D., PIPOLO, L., YANG, E., HANNAN, R.D. & THOMAS, W.G. (2004). Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol. Endocrinol., 18, 2344-2354.
47. PATACCHINI, R., SANTICIOLI, P., GIULIANI, S., GRIECO, P., NOVELLINO, E., ROVERO, P. & MAGGI, C.A. (2003). Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br. J. Pharmacol., 140, 1155-1158.
48. PAYSANT, J., RUPIN, A., SIMONET, S., FABIANI, J.N. & VERBEUREN, T.J. (2001). Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fund. Clin. Pharmacol., 15, 227-231.
49. RICHARDS, A.M. & CHARLES, C. (2004). Urotensin II in the cardiovascular system. Peptides, 25, 1795-1802.
50. RICHARDS, A.M., NICHOLLS, M.G., LAINCHBURY, J.G., FISHER, S. & YANDLE, T.G. (2002). Plasma urotensin II in heart failure. Lancet, 360, 545-546.
51. RUSSELL, F.D. (2004). Emerging roles of urotensin-II in cardiovascular disease. Pharmacol. Ther., 103, 223-243.
52. RUSSELL, F.D., MEYERS, D., GALBRAITH, A.J., BETT, N., TOTH, I., KEARNS, P. & MOLENAAR, P. (2003). Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am. J. Physiol., 285, H1576-H1581.
53. RUSSELL, F.D., MOLENAAR, P. & O'BRIEN, D.M. (2001). Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol., 132, 5-9.
54. SHENOUDA, A., DOUGLAS, S.A., OHLSTEIN, E.H. & GIAID, A. (2002). Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J. Histochem. Cytochem., 50, 885-889.
55. SONG, W., ASHTON, N. & BALMENT, R.J. (2003). Effects of single bolus urotensin II injection in anaesthetised rats. J. Physiol., 552P, P107.
56. TOTSUNE, K., TAKAHASHI, K., ARIHARA, Z., SONE, M., ITO, S. & MURAKAMI, O. (2003). Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci., 104, 1-5.
57. TOTSUNE, K., TAKAHASHI, K., ARIHARA, Z., SONE, M., MURAKAMI, O., ITO, S., KIKUYA, M., OHKUBO, T., HASHIMOTO, J. & IMAI, Y. (2004). Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides, 25, 1809-1814.
58. TOTSUNE, K., TAKAHASHI, K., ARIHARA, Z., SONE, M., SATOH, F., ITO, S., KIMURA, Y., SASANO, H. & MURAKAMI, O. (2001). Role of urotensin II in patients on dialysis. Lancet, 358, 810-811.
59. TZANIDIS, A., HANNAN, R.D., THOMAS, W.G., ONAN, D., AUTELITANO, D.J., SEE, F., KELLY, D.J., GILBERT, R.E. & KRUM, H. (2003). Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res., 93, 246-253.
60. VERGURA, R., CAMARDA, V., RIZZI, A., SPAGNOL, M., GUERRINI, R., CALO', G., SALVADORI, S. & REGOLI, D. (2004). Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn Schmiedeberg's Arch. Pharmacol., 370, 347-352.
61. WATANABE, T., PAKALA, R., KATAGIRI, T. & BENEDICT, C.R. (2001). Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 104, 16-18.
62. WATSON, A.M.D., LAMBERT, G.W., SMITH, K.J. & MAY, C.N. (2003). Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension, 42, 373-379.
63. WENYI, Z., SUZUKI, S., HIRAI, M., HINOKIO, Y., TANIZAWA, Y., MATSUTANI, A., SATOH, J. & OKA, Y. (2003). Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia, 46, 972-976.
64. WILKINSON, I.B., AFFOLTER, J.T., DE HAAS, S.L., PELLEGRINI, M.P., BOYD, J., WINTER, M.J., BALMENT, R.J. & WEBB, D.J. (2002). High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res., 53, 341-347.
65. ZOU, Y., NAGAI, R. & YAMAAKI, T. (2001). Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett., 508, 57-60.